J
Josep Vidal
Researcher at Carlos III Health Institute
Publications - 303
Citations - 9463
Josep Vidal is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 43, co-authored 261 publications receiving 7601 citations. Previous affiliations of Josep Vidal include University of Barcelona & Free University of Brussels.
Papers
More filters
Journal ArticleDOI
Practical recommendations for the management of diabetes in patients with COVID-19.
Stefan R. Bornstein,Francesco Rubino,Francesco Rubino,Kamlesh Khunti,Geltrude Mingrone,Geltrude Mingrone,David Hopkins,David Hopkins,Andreas L. Birkenfeld,Bernhard O. Boehm,Bernhard O. Boehm,Stephanie A. Amiel,Richard I. G. Holt,Jay S. Skyler,J. Hans DeVries,Eric Renard,Robert H. Eckel,Paul Zimmet,Kurt George Alberti,Josep Vidal,Bruno Geloneze,Juliana C.N. Chan,Linong Ji,Barbara Ludwig +23 more
TL;DR: An international panel of experts in the field of diabetes and endocrinology is formed to provide some guidance and practical recommendations for the management of diabetes during the COVID-19 pandemic.
Journal ArticleDOI
Glucagon-Like Peptide-1, Peptide YY, Hunger, and Satiety after Gastric Bypass Surgery in Morbidly Obese Subjects
Rosa Morínigo,Violeta Moizé,Melina M. Musri,Antonio M. Lacy,Salvador Navarro,José Luis Marín,Salvadora Delgado,Roser Casamitjana,Josep Vidal +8 more
TL;DR: The data show that RYGBP is associated with an improvement in the active GLP-1 and total PYY response to a liquid-meal intake, and provides circumstantial evidence for a potential role of these gastrointestinal hormones on the decreased appetite after RyGBP.
Journal ArticleDOI
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.
David Schellenberg,Clara Menendez,Elizeus Kahigwa,John J. Aponte,Josep Vidal,Marcel Tanner,Hassan Mshinda,Pedro L. Alonso +7 more
TL;DR: Intermittent sulphadoxine-pyrimethamine treatment was well tolerated and no drug-attributable adverse events were recorded and Serological responses to EPI vaccines were not affected by the intervention.
Journal ArticleDOI
Type 2 Diabetes Mellitus and the Metabolic Syndrome Following Sleeve Gastrectomy in Severely Obese Subjects
Josep Vidal,Ainitze Ibarzabal,Fabiola Romero,Salvadora Delgado,D. Momblán,Lilliam Flores,Antonio M. Lacy +6 more
TL;DR: SG is as effective as GBP in inducing remission of type 2 diabetes mellitus and the metabolic syndrome and the data suggest that SG and GBP represent a successful an integrated strategy for the management of the different cardiovascular risk components of the MS in subjects with T2DM.
Journal ArticleDOI
Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects.
Amanda Jiménez,Roser Casamitjana,Lilliam Flores,Judith Viaplana,Ricard Corcelles,Antonio M. Lacy,Josep Vidal +6 more
TL;DR: Roux-en-Y gastric bypass and SG are associated with comparable remission rates of type 2 diabetes mellitus, however, insufficient weight loss or weight regain in those with a more advanced disease may hamper the benefits of these surgical techniques on T2DM.